New system completes the Surity™  portfolio of external catheters for both men and women Integrates into daily routines to help support management of urinary incontinence at home Designed to operate quietly overnight, new Surity™ System helps minimize nighttime interruptions to support comfort and rest MÖLNDAL, Sweden, Aug. 19, 2026 /PRNewswire/ -- Wellspect HealthCare today announced the U.S. launch of the Surity™ Urinary Management System, a discreet at-home urine collection device designed to support people living with urinary incontinence and those who help care for them. This completes the full Surity™ portfolio in the U.S., following the introduction of the Surity™ Female and Male External Catheters earlier this year.

Empowered Funds LLC increased its holdings in DENTSPLY SIRONA Inc. (NASDAQ: XRAY) by 515.3% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 126,601 shares of the medical instruments supplier's stock after acquiring an additional 106,024 shares during the

DENTSPLY SIRONA NASDAQ: XRAY reported second-quarter 2026 revenue of $898 million, down 4.1% on a reported basis and 6.3% on a constant-currency basis, as the dental products company continued its turnaround plan amid lower volumes in several businesses and distributor inventory reductions in Europe.

DENTSPLY SIRONA's Q2 sales fall 4.1% as dental weakness offsets Wellspect growth, while margins improve and 2026 guidance is maintained.

The headline numbers for Dentsply (XRAY) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

DENTSPLY SIRONA Inc. (XRAY) Q2 2026 Earnings Call Transcript

Dentsply International (XRAY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.52 per share a year ago.

News Summary Reported net sales of $898 million Delivered GAAP gross margin of 54.9%, GAAP diluted earnings per share of $0.18 Achieved adjusted gross margin of 56.4%, adjusted EBITDA margin of 21.3%, adjusted EPS of $0.52 Announced expanded partnership with Medline Sinclair, broadening access to Connected Technology Solutions portfolio across Canada Repurchased 1.3 million shares of common stock during the quarter Reiterates 2026 outlook for net sales and adjusted EPS CHARLOTTE, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. ("Dentsply Sirona" or the "Company") (Nasdaq: XRAY) today announced its financial results for the second quarter of 2026.

Arkadios Wealth Advisors acquired a new position in shares of DENTSPLY SIRONA Inc. (NASDAQ: XRAY) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 74,961 shares of the medical instruments supplier's stock, valued at approximately $870,000. Several other large investors also recently made

XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.